LAM
ADPT icon

Lewis Asset Management’s Adaptive Biotechnologies ADPT Stock Holding History

Lewis Asset Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-19,500
Closed -$95.5K – 118
2023
Q4 		$95.5K Buy
+19,500
New +$89K 0.09% 109

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return

Lewis Asset Management's ADPT Position: Q1 2024 in Review

Lewis Asset Management sold out of Adaptive Biotechnologies (ADPT) in Q1 2024, closing a stake of 19,500 shares — an estimated $95.5K sold.

Lewis Asset Management first reported a position in ADPT in Q4 2023 and held it in 1 quarter. The position peaked at $95.5K in Q4 2023. 190 funds tracked by Wall St. Rank hold ADPT as of Q1 2024.

  • Lewis Asset Management reported no remaining Adaptive Biotechnologies position as of Q1 2024 after selling out during the quarter.
  • Lewis Asset Management sold 19,500 Adaptive Biotechnologies shares in Q1 2024, an estimated $95.5K.
  • Lewis Asset Management first reported a position in Adaptive Biotechnologies in Q4 2023 and held it in 1 quarter.
  • Lewis Asset Management's Adaptive Biotechnologies position peaked at $95.5K in Q4 2023.
  • 190 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2024.

Based on Lewis Asset Management's 13F filing for Q1 2024, filed 1 May 2024.